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Abstract
Background: Rapid clonal expansion of T cells occurs in response to antigenic challenges. The
kinetics of the T cell response has previously been described using tissue-based studies performed
at defined time points. Luciferase bioluminescence has recently been utilized for non-invasive
analysis of in vivo biologic processes in real-time.
Results: We have created a novel transgenic mouse model (T-Lux) using a human CD2 mini-gene
to direct luciferase expression specifically to the T cell compartment. T-Lux T cells demonstrated
normal homing patterns within the intact mouse and following adoptive transfer. Bioluminescent
signal correlated with T cell numbers in the whole body images as well as within specific organ
regions of interest. Following transfer into lymphopenic (RAG2-/-) recipients, homeostatic
proliferation of T-Lux T cells was visualized using bioluminescent imaging. Real-time bioluminescent
analysis of CD4+ T cell antigen-specific responses enabled real-time comparison of the kinetics and
magnitude of clonal expansion and contraction in the inductive lymph node and tissue site of
antigen injection. T cell expansion was dose-dependent despite the presence of supraphysiologic
numbers of OVA-specific OT-II transgenic TCR T-Lux T cells. CD4+  T cells subsequently
underwent a rapid (3–4 day) contraction phase in the draining lymph node, with a delayed
contraction in the antigen delivery site, with bioluminescent signal diminished below initial levels,
representing TCR clonal frequency control.
Conclusion: The T-Lux mouse provides a novel, efficient model for tracking in vivo aspects of the
CD4+  T cell response to antigen, providing an attractive approach for studies directed at
immunotherapy or vaccine design.
Background
T cell migration to sites of inflammation and infection is
essential for adaptive immunity and host protection. Cur-
rent methods of analyzing T cell migration and homing
primarily rely on obtaining mouse end-organ tissues and
subsequent detection of cells within these organs, either
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through in situ analysis by immunohistologic methods or
by isolation and analysis of recovered T cells from dis-
rupted tissues. While each of these approached offers
unique advantages (and disadvantages), neither permits
"real-time" analysis of T cell dynamics following antigenic
exposure and is limited to specific time points and tissues
chosen for study. Bioluminescent imaging represents a
powerful alternative for the monitoring immune cell
homing and migration in vivo that does not require ani-
mal sacrifice for analysis.
Luciferase proteins produce light in the visible spectrum
(approximately 560 nm for firefly luciferase) following
interaction with luciferin substrate molecules. This reac-
tion only requires ATP and oxygen and thus can occur in
any actively metabolic cell. Luciferin, a small water-solu-
ble molecule, readily crosses cell membranes and can pen-
etrate into virtually all tissues. Light produced by the
luciferase-luciferin reaction is detectable by low-light
detection devices, such as charge-coupled device
(CCD)4cameras. Bioluminescence imaging is a good
model for in vivo imaging based on the low background
signal, since it only detects chemical reactions between
the enzyme and substrate. Bioluminescence also requires
relatively short imaging times (seconds to minutes), is
easy to use, and the instrumentation is relatively inexpen-
sive [1,2].
Luciferase imaging techniques have previously been used
to track localization of bacterial and viral pathogens,
monitor therapeutic responses in tumor xenografts, and
allograft cell survival [3-6]. Recent studies have utilized
bioluminescence to track T cell homing patterns following
adoptive transfer of luciferase-expressing allogeneic T cells
into MHC-mismatched recipient mice [7,8]. We have also
reported use of luciferase-expressing CD8 T cells for anal-
ysis of population dynamics in response to viral-based
antigenic-challenge [9]. These studies reveal that T cell
proliferation, in the context of graft versus host disease or
viral infection, can be visualized in 'real-time' within
recipient mice. The luciferase-expressing T cells can also
be identified within specific tissue sites in order to deter-
mine homing and migration kinetics over time [7,8].
In the current study, we describe the generation of a trans-
genic mouse (T-Lux) model in which the luciferase gene is
specifically expressed by T cells, thereby permitting analy-
sis of T cell population dynamics in living mice in real-
time. By crossing the T-lux transgenic mice with OVA-spe-
cific CD4 TCR transgenic mice (OT-II), we have generated
a reporter model with which to track antigen-specific CD4
T cells in vivo, in real-time. Our studies reveal the popula-
tion dynamics of the CD4 clonal response within draining
lymphoid tissues and antigen injection sites in individual
mice and demonstrate the utility of this model for non-
invasive analyses of T cell clonal responses.
Methods
Mice
C57BL/6 and C57BL/6.Ly5.2 (CD45.1+) mice were
obtained from Jackson Laboratory (Bar Harbor, ME).
Thy1.1-expressing C57BL/6 mice were obtained from
Charles River Breeding Laboratories. Mice used for imag-
ing were placed on a low light diet (Harlan Tekland) to
reduce non-specific luminescence. All mice were housed
or bred in our specific pathogen-free facility, and were ini-
tially used at 6–10 weeks of age. All mice were housed and
treated according to National Institutes of Health guide-
lines under the auspices of the UAB Institutional Animal
Care and Use Committee (IACUC) of the University of
Alabama at Birmingham.
Generation of T-lux transgenic mouse
The luciferase coding sequence was excised from the pGL3
plasmid (Promega) by Xba I/Nco I digestion, blunted
with Klenow and ligated into a Sma I-linearized hCD2
minigene cassette plasmid (the kind gift of Dr. Dmitri
Kioussis; [10]). The T-lux transgene was restriction
mapped for correct orientation and sequenced across the
integration joints to confirm the correct reading frame
and terminus of the luciferase gene (using primers
OCW938 and OCW939). The reporter gene construct was
introduced into single-cell embryos of donor C57BL/6
mice by pronuclear injection in the UAB Transgenic
Mouse Facility. Potential founder lines were screened by
luminescence analysis of peripheral blood. Red blood
cells were lysed from 30 μL of blood using ACK buffer for
2 minutes. Cells were then plated into 96-well plates and
luciferin (100 μg/ml) added to each well 10 minutes prior
to imaging. Bioluminescence imaging of the plates was
performed using the IVIS® Imaging System with stage at 15
cm height for 600 seconds. One founder line (T-lux 9)
with readily detectable luminescence that transmitted the
transgene in the germline was selected for subsequent
studies.
Antibodies
The following antibodies were used for fluorescence label-
ling of cells for flow cytometric analyses: fluorescein iso-
thiocyanate (FITC)-labelled anti-mouse CD8 (clone 53-
6.7); phycoerythrin (PE)-labelled anti-mouse CD4 (RM4-
5); PE-labelled anti-mouse CD45.2 (104); biotin-labelled
anti-mouse CD8 (H35-17.2) and CD45.1 (A20). All were
purchased from eBiosciences (San Diego, CA). PerCP-
labelled anti-mouse CD3 (145-2C11) was purchased
from BD Pharmingen (San Jose, CA).
Flow cytometric analysis
Single cell suspensions from specified target organs were
analyzed by FACS at the indicated time points. Cells were
stained for flow cytometry with FITC-, PE-, PerCP-, or
biotin-conjugated mAbs indicated in the appropriate fig-
ure legends. Cells labelled with biotinylated primary AbBMC Immunology 2009, 10:44 http://www.biomedcentral.com/1471-2172/10/44
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were detected with allophycocyanin-conjugated streptavi-
din. For analytical flow cytometry, at least 100,000 events
with forward and side scatter properties of lymphocytes
were collected on a FACSCalibur flow cytometer (BD Bio-
sciences, San Jose, CA) and analyzed using CellQuest soft-
ware (BD Biosciences, San Jose, CA). Some analyses were
performed using FlowJo software (Treestar, Inc, Ashland,
OR).
Isolation and Transfer of T-lux Cells
Splenocytes were harvested from T-lux mice and CD4+ T
lymphocytes isolated using Dynal Bead Separation
(Dynal Biotech LLC), according to manufacturer's instruc-
tions. Briefly, T-lux splenocytes were incubated with CD4+
specific magnetic beads for 20 minutes at 4°C. The cell-
attached beads were then incubated with Detach-a-bead
at room temperature for 1 hour. Thoroughly washed cells
were counted, resuspended in RPMI medium without
serum, and transferred to recipient mice via tail vein injec-
tion.
In vivo Bioluminescence Imaging of Mice
Mice were anesthetized with isofluorane gas and placed in
a light-tight chamber. A photographic (gray-scale) refer-
ence image was obtained at 10 minutes after D-luciferin
injection (2.5 mg intraperitoneal); bioluminescent
images were collected immediately thereafter. Images
were obtained with a CCD camera cooled to -120°C,
using the IVIS®  100 Imaging System (Xenogen Corp.,
Alameda, CA) with the field of view set at 10 cm height.
The photographic images used a 0.2 second exposure, 8f/
stop, 2 binning (resolution), and an open filter. The bio-
luminescent images used exposures ranging from 120 to
600 seconds, 1f/stop, 8 binning and open filter. The bio-
luminescent and gray-scale images were overlaid using
Living Image software (Xenogen Corp.). Igor image anal-
yses software (Wavemetrics, Lake Oswego, OR) was also
used to obtain a pseudocolor image representing biolumi-
nescence intensity (blue, least intense, and red, most
intense). Regions of interest were drawn around organs
and the total counts (photons) were summed in the entire
organ areas. The total counts in each region of interest
were normalized to total acquisition time to obtain
counts/sec.
Results
Transgenic mice containing the firefly luciferase gene, luc, 
under control of a human CD2 mini-gene cassette produce 
T cell-specific bioluminescence
The human CD2 (hCD2) minigene cassette has previ-
ously been utilized to direct transgene expression in
mouse T cells [10-12]. The hCD2 minigene contains an ~5
kb 5' flanking/promoter region and a 5.5 kb 3' region that
contains a locus control region (LCR). The LCR of the
hCD2 contains a T cell-specific enhancer and additional
regulatory elements responsible for establishing an active
chromatin domain in T lymphocytes [12]. The intact first
intron of human CD2, located downstream of the pro-
moter region, improves efficiency of transgene expression.
Transgene expression levels are typically independent of
the integration site, and the level of expression is propor-
tional to the number of transgene copies [11].
Firefly luciferase gene, luc, was inserted into the partial
second exon of hCD2 minigene (Figure 1A). The trans-
gene was then injected into the pronuclei of single-cell
embryos from C57BL/6 female mice. Two rounds of injec-
tions resulted in 24 mice. Red blood cell-depleted periph-
eral blood was imaged after the addition of luciferin,
using the IVIS® imaging system. Four founder mice that
displayed luciferase expression were identified (T-lux
founder lines 9, 16, 20, and 23) (Figure 1B and 1C). One
of these founders, T-lux founder #9, transmitted the trans-
gene in the germline and displayed T lineage-specific
expression (below), and was used for all subsequent stud-
ies.
The distribution of luciferase-expressing cells was deter-
mined in intact founder mice. Bioluminescent imaging
revealed increased signal within lymphoid tissue regions
(Figure 1D). As anticipated, bioluminescence was
detected from the thymus, as well as spleen, peripheral
lymph nodes (LNs), and gastrointestinal lymphoid tis-
sues, consistent with normal lymphocyte homing patterns
[13-15]. Light emission from circulating T cells and skin T
cells delineated the anatomical outlines of the mouse.
Splenocytes from T-lux transgenic mice were isolated in
order to determine the lineage specificity of the luciferase
transgene. Splenocytes were separated by FACS into four
populations, CD4+, CD8+, B220+, and a triple-negative
population. The FACS purity of the sorted populations of
CD4+ and CD8+ were 98% and 99%, respectively, while
the B220+ and the negative populations were 96% and
90% pure. Cells were plated into 96-well plates in equiv-
alent numbers of each population (1 × 106 cells/well) and
were imaged for bioluminescence ex vivo. As shown in Fig-
ure 1E, bioluminescent signal was almost exclusively
within the CD4+ and CD8+ T cell populations. Quantifica-
tion of light emission of these cell populations confirmed
the purity of the sort. Ratios of CD4:B220 and CD4:nega-
tive show a 4% and 5% bioluminescent signal, respec-
tively. These numbers are consistent with the low level of
T cell contamination of these populations detected by
FACS analysis. T-lux T cells retained normal T cell prolif-
eration in response to TCR stimulation and produced sim-
ilar levels of cytokines compared to wild-type T cells (data
not shown). Thus, the T-lux transgene produces a detecta-
ble bioluminescent signal that is limited to the T cell com-
partment, and does not alter T cell function in these cells.BMC Immunology 2009, 10:44 http://www.biomedcentral.com/1471-2172/10/44
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T-lux CD3+ T cells rapidly home to secondary lymphoid 
tissues and produce a stable luciferase signal within 24 
hours following adoptive transfer
Naïve T cells are excluded from non-lymphoid tissues and
preferentially home to secondary lymphoid organs [16].
Expression of CD62L and CCR7 allow for recognition and
binding to the high endothelial venules within lymphoid
tissues [17,18]. T cells typically reside within the lymph
nodes for approximately 24 hours before re-entering the
circulation unless activated by dendritic cells [19,20].
Until antigen is encountered, these T cells will migrate
randomly between secondary lymphoid tissues [21].
The ability to monitor T cell signal within the live mouse
over time provides an opportunity to efficiently analyze T
cell distribution kinetics serially in single mice, eliminat-
T-lux Transgenic Mouse Model Figure 1
T-lux Transgenic Mouse Model. Shown in (A) is a diagrammatic representation of the CD2.luc transgene. The luc gene is 
located downstream of the 5 kb promoter region and the intact first intron (in red). The CD2.luc transgene was introduced 
into single-cell embryos of C57Bl/6 mice by standard transgenesis. Equal numbers of peripheral blood mononuclear cells from 
potential founder lines were screened for luciferase activity in 96 well plates (B). Numbers in positive wells indicate founder 
line. Actual light emission results are shown in (C), confirming positivity of founder lines #9, 16, 20, and 23. (D) Whole-body 
bioluminescence image of a transgenic 'T-lux' mouse. A strong primary lymphoid tissue bioluminescent signal (thymus) and sec-
ondary lymphoid tissue signal (spleen, mesenteric lymph nodes (LNs), and peripheral LNs) is seen. Pseudocolor scale is shown 
to right of image. Lineage specificity of transgene expression was confirmed by FACS sorting of splenocytes into four popula-
tions, each containing 1 × 106 cells (E). These populations were: CD4+ T cells, CD8+ T cells, B220+ (B cells), and CD4-CD8-
B220- (non-T, non-B cells). A representative bioluminescent image of wells containing each sorted cell population is shown 
below figure.BMC Immunology 2009, 10:44 http://www.biomedcentral.com/1471-2172/10/44
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ing the need for use of large cohorts of mice that can be
analyzed only at individual time points. To test the hom-
ing characteristics of the T-lux T cells following adoptive
transfer into immunocompetent mice, we transferred 1 ×
107 T-lux CD3+ cells into CD45.1, non-irradiated B6 recip-
ients (n = 8). Individual recipient mice were imaged
beginning 15 minutes post-transfer and at the indicated
time intervals (Figure 2A). Detectable signal was present
within the peripheral and mesenteric lymph nodes as
early as 15 min following adoptive transfer, consistent
with previously published studies [20]. A splenic signal
was also visible prior to 1 hour after transfer in anterior-
posterior (AP) image orientations, and was readily detect-
able 15 min post-transfer in left lateral images (not
shown).
Bioluminescent signal (counts/sec) was calculated in
order to quantitate the bioluminescent signal intensity
change over time, as T cell migratory patterns can be delin-
eated by analyzing the signal flux within different regions
of measurement. When the signal flux ceases to change, it
can be concluded that pool size homeostasis has been
achieved in the anatomical regions of interest. We col-
lected and graphed whole body light emission measure-
ments over time and assessed migratory trends of T-lux T
cells. Following a brief decrease in signal due to redistri-
bution following injection, whole body bioluminescence
increased, reaching a plateau between 12 and 24 hours
(Figure 2B). Notably, signal intensity in the intestinal
lymphoid tissues equilibrated more rapidly (1–3 hours
post-transfer), consistent with more rapid recruitment to
these tissue sites prior to redistribution, whereas signal
intensities in other secondary lymphoid tissues equili-
brated by ~12 hours post-transfer (Figure 2A, and data not
shown). There was no detectable early enrichment in the
lung fields, indicating that no significant trapping of
transferred T cells in the pulmonary capillary beds was evi-
dent.
Correlation of bioluminescent signal intensity with T cell 
distribution in vivo
To determine the relationship between bioluminescent
signal and T cell numbers in the T-lux mouse, the per-cell
signal intensity was defined under non-attenuating condi-
tions in vitro to provide a baseline for subsequent in vivo
studies. In vitro, T-lux spleen and peripheral lymph node
T cells were added to a 96-well plate in decreasing cell
numbers from 1 × 107 to 1 × 104 CD3+ cells. Biolumines-
cent signal was quantified for each population (Figure
3A). A comparison of signal strength (counts/sec) and T
cell numbers demonstrated a linear relationship (r2 =
0.998) (Figure 3B), and the per-cell signal intensity was ≈
0.225 counts/cell/sec.
The signal of T cell bioluminescence within the intact
mouse was assessed following adoptive transfer of luci-
ferase-expressing cells. Initial studies were designed to
analyze whole body bioluminescent signal generated by
differing numbers of T-lux T cells. Increasing numbers of
CD3+ T-lux cells (1 × 106, 3 × 106, and 1 × 107; n = 3) were
injected via tail vein into congenic C57BL/6 recipients.
Bioluminescent imaging of the entire mouse was per-
formed at 12, 24, and 72 hours following transfer. Repre-
sentative images obtained at 72 hours are shown in Figure
3C. Stable bioluminescent signals in the abdominal
region, spleen, and cervical lymph node regions were
present by 12 hours post-transfer (data not shown). Com-
parison of whole body counts/sec versus T-lux cell dose
confirmed a linear and proportional relationship (Figure
3D).
Subsequent experiments were performed to determine the
correlation of T cell number to bioluminescent signal
within specific anatomical tissue regions. T cells (3.5 ×
106) were obtained from CD45.2+ T-lux mice and intro-
duced into congenic CD45.1+ C57BL/6 recipients. Use of
the CD45 allelic marker allowed discrimination by FACS
of the donor CD45.2-expressing T-lux cells. Recipient
mice were imaged every three days in defined anatomical
regions following T cell redistribution to secondary lym-
phoid tissues. Direct analysis of transgenic T cell numbers
in those sites by flow cytometry was then performed and
compared to the luciferase bioluminescent signal (Figure
4).
The peripheral lymph node (inguinal and axillary)
regions of interest (ROIs) generated an observable signal
following T cell transfer (3.5 × 106) at all time points (Fig-
ure 4). Comparison of signal strength to T cell numbers
resulted in a 1.54 counts/cell/sec ratio (Table 1). Cervical
lymph nodes produced similar results of 1.06 counts/cell/
sec. By comparison, the signal to cell ratio within the
spleen was reduced in AP positioning (0.075 counts/cell/
sec), consistent with increased attenuation of luciferase
signal from T cells resident in the deeper tissues (Table 1),
although on lateral view, this attenuation was not appar-
ent (data not shown).
Signal to cell ratios from mesenteric lymph nodes surpris-
ingly revealed an increased signal to cell ratio (2.04
counts/cell/sec) compared to superficial lymph nodes
(Figure 4 and Table 1). This is likely due to a contribution
of additional signal from other lymphoid tissues within
the gut, producing a "generalized" signal. Additional
experiments were performed on mice after surgically
opening the abdomen under anesthesia and exposing
intestinal tissue. These "open" images revealed T-lux sig-
nal within individual Peyer's patches and other regions
not clearly seen within the overall abdominal signal (data
not shown). Collectively, these experiments demon-
strated the ability to quantify T cell numbers in situ in real-
time using bioluminescence, and although the signalBMC Immunology 2009, 10:44 http://www.biomedcentral.com/1471-2172/10/44
Page 6 of 14
(page number not for citation purposes)
Kinetics of Tissue Localization following Adoptive Transfer of T-lux T cells Figure 2
Kinetics of Tissue Localization following Adoptive Transfer of T-lux T cells. The kinetics of naïve T cell homing were 
assessed following adoptive transfer of 1 × 107 T-lux CD3+ cells into CD45.1-positive, C57BL/6 recipients (N = 8). Recipient 
mice were imaged for whole body bioluminescence at timed intervals following transfer. (A) Representative images from a sin-
gle mouse for each of the indicated time points. Additional reference anatomical map shown below 24-hour time point. Pseu-
docolor scales are shown to right of figures. The mean bioluminescent signal of the cohort for each time point is displayed in 
(B). Control bioluminescence from mice receiving non-transgenic T cells ('non-lux' T cells) is also shown. Error bars indicate 
SEM.
  	
  	  
A.
B.BMC Immunology 2009, 10:44 http://www.biomedcentral.com/1471-2172/10/44
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intensity per cell varied depending on anatomic location,
the calculated values proved reliable for estimating T cell
number in each site at different time points in the same
animal, and even between individual mice that received
comparable T cell transfers.
Tracking homeostatic proliferation in lymphopenic hosts
Normal T cells undergo extensive homeostatic prolifera-
tion in a lymphopenic setting. Expansion of T cells follow-
ing transfer into an immunodeficient host can be due to
both thymic-dependent and -independent mechanisms
[22]. An essential role for interleukin-7 in thymic-inde-
pendent expansion of T cells has been well described
[23,24]. The luciferase-expressing T-lux mouse provided a
model to visualize homeostatic T cell expansion over time
within the live host.
We transferred 1 × 107 T-lux CD3+ cells into C57BL/6
RAG-deficient (RAG-/-) mice (n = 4), which lack mature T
and B cells. Reconstituted RAG-/- mice were then imaged
Correlation of T Cell Dose and Luciferase Bioluminescent Signal Figure 3
Correlation of T Cell Dose and Luciferase Bioluminescent Signal. A comparison of T-lux T cell numbers with light 
emission signal was done both in vitro and in vivo to assess the sensitivity of the T cell luciferase signal. (A) Pooled CD3+ T cells 
from spleen and peripheral lymph nodes of T-lux mice were plated in triplicate (in columns) into a 96-well plate at the indicated 
cell numbers per well, and light emission was quantitated following addition of luciferin. Pseudocolor scale is shown to right. 
(B) Plot of light emission data from (A) versus input T cell numbers. Error bars indicate standard error of the mean (SEM). 
Medium alone was used as negative control. The r2 value for data is displayed on figure (see text for details). (C) CD3+ T cells 
isolated from pooled spleen and LN of T-lux mice were adoptively transferred into congenic C57BL/6 recipients. Whole body 
bioluminescence was quantified at 12, 24, and 72 hours post-transfer. Representative images from 72 hours post-transfer are 
shown for three cell doses. (D) Whole body luminescence was plotted against transferred T cell numbers in (C). A represent-
ative plot is shown for the 72-hour time point.BMC Immunology 2009, 10:44 http://www.biomedcentral.com/1471-2172/10/44
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for bioluminescent signal at the indicated time points
post-transfer. Whole body bioluminescent images
revealed rapidly increasing signal during the first two
weeks following transfer (~100-fold increase), followed
by plateau. Comparison studies performed with transfers
of 1 × 107 T-lux CD3+ cells into WT C57BL/6 mice showed
that, in contrast to the luciferase signal in the lympho-
penic RAG-/- mice, immunocompetent mice showed a
modest decline in luciferase signal after two days, fol-
lowed by a relatively stable signal over the ensuing three
weeks (Figure 5). In the RAG-deficient recipients, the T
cell signal was evident in both lymphoid and non-lym-
phoid tissues, consistent with some degree of memory T
cell development and distribution. Whole body biolumi-
nescence signal from reconstituted RAG-/- mice was
approximately 20% of the intact, wild-type T-lux mouse.
In vivo Bioluminescent Signal Within Different Lymphoid Tissues Figure 4
In vivo Bioluminescent Signal Within Different Lymphoid Tissues. To determine the correlation between T-lux T cell 
numbers and bioluminescent signal in vivo, we adoptively transferred T-lux CD3+ cells (3.5 × 106) into CD45.1-positive, con-
genic B6 recipients. Three days post-transfer, light emission was determined for whole body, as well as defined anatomical 
regions (Regions of Interest, or ROI), including cervical, peripheral, and mesenteric lymph nodes and spleen, and compared to 
actual T cell numbers recovered from these tissues. FACS analysis was performed on cells obtained from recipient mice and 
representative plots are shown (left panel). Tissue source is indicated for each FACS plot. Cells were first gated on live CD3-
positive lymphocytes. Recipient CD45.1 allotype is shown on the y-axis and donor CD45.2 on x-axis. Numbers indicate the 
percentages of donor (T-lux) T cells of the total live CD3+ T cells in each tissue. The composite of bioluminescence images 
(right panel; left image) shows a non-normalized pseudocolor image, with the analyzed ROIs indicated by arrows; the same 
pseudocolor image is overlayed on a photographic image of the mouse (right panel; right image).BMC Immunology 2009, 10:44 http://www.biomedcentral.com/1471-2172/10/44
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This finding correlated with the relative total T cell num-
bers when organs were harvested and transferred cells
counted (data not shown).
Non-invasive tracking of T cell half-life
Diversity of the T cell receptor repertoire is essential for
protection of the host from infection. Previous studies
have demonstrated that the number of cells bearing the
same MHCII:peptide-specific TCR within the naïve CD4+
T cell repertoire is in the range of 20–200 [25]. This same
group also demonstrated that survival of CD4+ T cells in
vivo is determined in part by TCR specificity attributes, but
also clonal frequency, with an inverse relationship
between T cell number and half-life. The half-life of adop-
tively transferred polyclonal CD4+ T cells within second-
ary lymphoid tissues was calculated to be 124 days [26].
Whole body bioluminescent imaging using T-lux T cells
provided a non-invasive method of measuring the half-
life of T cells within the entire mouse. Adoptive transfer
studies were performed by infusing 3.5 × 106 polyclonal
naïve T-lux CD3+ cells (CD45.2-positive) into CD45.1-
positive, B6 mice. Bioluminescent imaging was performed
on recipient mice every other day, beginning 1 day post-
transfer and for a total of 33 days, and in some studies
extended for a total of 120 days. As seen in Figure 6A,
there was a progressive decline in bioluminescent signal
from individual mice following transfers. In extended
experiments, the T cell half-life calculated on the basis of
decay in luminescent signal yielded a calculated half-life
of ~120 days, in good agreement with published data
[26]. Further, the decline in signal did not appear to be
due to active immune clearance, as parallel studies using
non-transgenic, CD45.2-positive, CD3+ T cells transferred
into CD45.1 B6 recipients demonstrated a comparable
decline in T cell numbers as determined by FACS analysis
of lymphoid tissues (data not shown).
We next determined whether there was stability of single-
cell luciferase signal by T-lux cells following adoptive
transfers. After transfer of 3.5 × 106 T-lux CD3+ cells, we
imaged distinct regions of interest (ROIs) for peripheral,
cervical, and mesenteric lymph nodes. Spleen was not
included in this analysis due to the attenuation of signal
previously demonstrated in AP determinations. We
obtained bioluminescent signal measurements from all
ROIs every 3 days for 5 weeks. We then quantified T cell
numbers from each region using flow cytometric analyses
at the indicated time points post-transfer based on the
CD45.2 marker, and calculated the counts per cell pro-
duced within these lymphoid organs (Figure 6B). The
ratio of counts/cell remained constant despite the decline
in overall transferred cell numbers, indicating that signal
loss was due to decline in the number, not single-cell
intensity, of luciferase-expressing cells. Thus, the luci-
ferase reporter appears to be stable for prolonged periods
following adoptive transfer and shows no evidence of pro-
voking an alloantigenic response, at least in the C57BL/6
strain background.
Whole body imaging of clonal CD4+ T cell response to 
antigen
After encountering antigen, CD4+ T cells undergo marked
clonal expansion followed by a contraction phase on
clearance of antigen [27]. The T-lux mouse represents a
novel model for the analysis of T cell dynamics following
antigen encounter. To study the CD4+ T cell antigen-spe-
cific response in individual mice, we crossed the T-lux
mouse with the OT-II TCR transgenic mouse [28], and
transferred T-lux-OT-II T cells into immunocompetent
congenic recipients. OVA peptide emulsified in a non-
toxic, multiple emulsion adjuvant (ME) [29], or adjuvant
alone, was injected into the footpad of recipient mice and
the clonal CD4+  T cell response imaged over time
(Figure 7).
Quantification of the bioluminescent signal was per-
formed for the draining lymph nodes (LNs), non-draining
(contralateral) LNs, dorsal injected footpad, as well as
Table 1: Detection Efficiency of T-Lux T cells
Region of Interest (ROI) Mean counts/cell/sec (Stdeva)
Cervical lymph nodes 1.06 (0.14)
Mesenteric lymph nodes 1.54 (0.20)
Peripheral lymph nodes 2.04 (0.25)
Spleenb 0.075 (0.015)
a Stdev, standard deviation
b Anterior-posterior (AP) imaging view
Homeostatic Proliferation of T-lux Cells Figure 5
Homeostatic Proliferation of T-lux Cells. T-lux CD3+ T 
cells (1 × 107) were transferred to WT, congenic C57BL/6 
(B6) mice (N = 8), denoted 'immunocompetent,' or RAG-
deficient (RAG-/-) B6 mice (N = 4), denoted 'lymphopenic.' 
Whole body bioluminescent imaging was performed at the 
indicated intervals post-transfer for a total of 24 days, and 
light emission was determined for both groups. Error bars 
indicate SEM.BMC Immunology 2009, 10:44 http://www.biomedcentral.com/1471-2172/10/44
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whole body and other regions of interest. Strict gating on
the injection site (footpad) was performed to isolate injec-
tion site signal from the draining popliteal node signal
(Additional File 1). Bioluminescent signal was analyzed
over time for each of these sites (Figure 7B). Increased T
cell signal was first demonstrated in the draining lymph
node at day 1 (24 hours after OVA injection). This signal
was greater in the group given 300 μg OVA compared to
100 μg (Figure 7B). Increased signal in the draining lymph
node preceded T cell migration to the injection site by 1–
2 days, with increasing signal at the injection site apparent
on day 3. This pattern is consistent with previous studies
demonstrating T cell expansion within the draining
lymph node followed by migration and accumulation
within non-lymphoid tissue sites [20,30,31]. T cell biolu-
minescent signal in both these regions, as well as whole
Half-Life and Signal Stability of Transferred T-lux Cells In Vivo Figure 6
Half-Life and Signal Stability of Transferred T-lux Cells In Vivo. (A) T-lux T cells (3.5 × 106 cells) were adoptively 
transferred into congenic C57BL/6 (B6) mice (N = 8), and whole body bioluminescent imaging was obtained at the indicated 
times post-transfer. Control mice were given non-transgenic T cells; a representative day 5 image obtained from control 
mouse is shown to far right. (B) 3.5 × 106 T cells from CD45.2+ T-lux mice were adoptively transferred into congenic, CD45.1+ 
B6 mice and tissue-specific light emission quantitated. Light emission was calculated at the indicated times post-transfer for spe-
cific regions of interest (ROIs), including peripheral, cervical, and mesenteric (gut) lymph nodes. T-lux T cell numbers from 
recovered tissues were determined by flow cytometric quantitaton of CD45.2+ cells, and counts/sec per T cell were calculated. 
T-lux bioluminescent emission (counts/cell) within the indicated regions of interest is plotted over time. Error bars indicate 
SEM.BMC Immunology 2009, 10:44 http://www.biomedcentral.com/1471-2172/10/44
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body, peaked at day 7 and showed similar patterns of
decreasing signal by day 10–12, although residual signal
was evident in the injection site for several days after
attenuation of signal in the draining LN. T cell signal was
higher in whole body, draining lymph node, and footpad
regions in those mice given 300 μg compared to 100 μg
OVA injections (Figure 7B). The non-draining lymph
node showed minimal increase in signal (Figure 7B), but
notably, other distal LNs demonstrated significant signal
increase at the peak of the response (eg, cervical and
mesenteric LNs, day 7). T cell migration to non-lymphoid
tissues was largely restricted to the injection site, with
minimal apparent trafficking to other tissue sites (Figure
7A). Notably, the T cell signal was substantially higher in
the injection site than in the draining LNs at the respective
peaks of signal intensity, suggesting that T cells activated
in the draining LNs rapidly trafficked to the site of anti-
gen/adjuvant injection and accumulated there before
declining in number. Given that the large majority of the
total body signal was accounted for in the draining LNs
and injection site, the rapid decrement in signal after day
7 indicates cell loss, rather than redistribution to other tis-
sue sites. Thus, following the contraction phase, T cell bio-
luminescent signal diminished to levels comparable to
that of the pre-injection levels (day -1) and those of sham
(adjuvant only) injected mice.
Discussion
T cells undergo a complex pattern of clonal proliferation
and expansion following primary and secondary anti-
genic challenges [32-35]. Using luciferase-expressing OT-
II T cells, we were able to monitor antigen-specific CD4+ T
cell dynamics serially in the same animal. In accord with
previous reports, our results demonstrated initial expan-
sion within the draining lymph node followed rapidly by
migration and accumulation within a footpad injection
site [20,30]. Notably, and in agreement with a previous
study [30], we find that overwhelmingly the T cells that
leave the lymph node draining the site of antigen injec-
tion migrate to the antigen injection site, although some
enhanced accumulation of cells in other secondary lym-
phoid tissues is evident. Despite early increases in T cells
numbers in the draining lymph nodes, T cell numbers
within both the draining lymph node and the injection
site demonstrated a peak 7 days after injection, followed
by a rapid decline in signal intensity both in the draining
lymph nodes and injection site that was only marginally
delayed kinetically in the latter. The concordance of the
peak of T cell expansion in the draining lymph node and
injection site in our study is somewhat different from pre-
vious studies, which demonstrated a more prolonged
time course [20] and kinetic delay between peak T cell
numbers in draining lymph node and injection site. This
likely reflects the more rapid clearance of the antigen-
adjuvant depot in our study, as the ME adjuvant is far less
viscous and is more rapidly cleared from tissue sites than
the oil-based emulsions used in previous studies (unpub-
lished observations). This highlights the importance of
sustained antigen in the injection site to prolong recruit-
ment and/or survival of immigrating T cells attracted to
the site of antigen delivery [30].
In the current study, there was no detectable redistribu-
tion of CD4 T cell signal to non-lymphoid tissues follow-
ing clonal contraction in the draining LNs and injection
site, which is in contrast to previous studies wherein anti-
gen and adjuvant were delivered systemically, or in stud-
ies of the CD8 response to viral infection. Again, this
likely reflects differences in the distribution and kinetics
of antigen clearance in the different studies. This may also
reflect characteristics of the OT-II TCR transgenic model,
clonotypic T cells from which have a relatively low avidity
for the MHC-OVAp complex that may allow endogenous
clones reactive to OVA peptide to out-compete the OT-II
response over time. Future studies, following crosses of
the T-lux reporter transgene with other TCR transgenic
specificities should help address this. In any case, given
the relative technical ease with which T cell clonal dynam-
ics can be monitored using the T-lux model, efforts to
implement these types of single animal longitudinal stud-
ies represents a significant advance for conducting studies
of adjuvant type and delivery for future studies, with
attendant advantages for optimizing future vaccine thera-
pies for infectious agents and cancer.
Homeostatic proliferation of mature T cells occurs within
the lymphopenic host and has been shown to be associ-
ated with a concomitant shift toward memory phenotypes
(reviewed in [36]). T cell expansion in this setting has
been shown to be due to IL-7 [23,24] and IL-15/IL-2-
dependent mechanisms [37]. IL-15, in particular, has
been demonstrated to induce a memory phenotype in
CD8+ T cells that is associated with an alteration of cell
homing receptors [38,39]. It is not surprising; therefore,
that we observed T cell expansion and localization of T-
lux cells within non-lymphoid tissues following transfer
into the RAG-deficient mice. Localization within non-
lymphoid tissues as well as the activation profile of these
cells has important implications in immune reconstitu-
tion following infection and bone marrow transplanta-
tion, and implementation of the T-lux model for efficient
characterization of this process is demonstrated herein.
Bioluminescent imaging technology provides a mecha-
nism to observe T cell homing and specific CD4+ T cell
immune responses in vivo, in real-time in individual ani-
mals. This technique eliminates the need for large groups
of mice terminated at varying time points, reducing ani-
mal usage and cost. In addition, this provides a method to
efficiently observe and quantitate T cell responses in all
tissue sites simultaneously, providing a window on T cell
response dynamics not easily achieved using approachesBMC Immunology 2009, 10:44 http://www.biomedcentral.com/1471-2172/10/44
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Clonal T cell Response to Antigen in vivo Figure 7
Clonal T cell Response to Antigen in vivo. Naïve CD4+ T cells were isolated from OT-II.T-lux transgenic mice (5 × 106) 
and transferred into congenic, WT B6 mice on day -2. Following baseline bioluminescent imaging on day -1, mice were given 
footpad injections of 100 μg or 300 μg of OVA peptide in ME adjuvant (red arrows; day 0). Control mice were given sham 
footpad injections containing adjuvant only (indicated as 0 μg OVA). Bioluminescence imaging was performed on all mice at the 
indicated time points. Representative images are shown for mice receiving 300 μg OVA peptide (A). The time of acquisition is 
shown above individual images ("d" indicates days). Bioluminescence emission (counts/sec) was quantified for all OVA doses 
and analyzed over time for various regions of interest. Shown in (B) are draining inguinal lymph node, non-draining inguinal 
lymph node, footpad injection site, and whole body. Error bars indicate SEM.BMC Immunology 2009, 10:44 http://www.biomedcentral.com/1471-2172/10/44
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that require tissue disruption for localization and quanti-
tation of T cells. Also, given the lack of alloreactivity of the
luciferase reporter molecule in the C57BL/6 strain, the T-
lux mouse provides an excellent method for long-term
immune studies following adoptive transfer. We have
monitored T-lux T cell survival up to 75 days following
adoptive transfer and found no evidence of immune clear-
ance in re-transfer studies (Figure 6C, and data not
shown). Previous studies in rats have demonstrated the
absence of immunogenicity of firefly luciferase using
transgenic tissue allografts [40]. In contrast, studies using
green fluorescence protein (GFP), another biolumines-
cent tracking molecule, have demonstrated an immune
response to the molecule and decreased lifespan for GFP-
expressing cells [41]. Thus, the T-lux mouse is ideal for
model systems investigating long-term immune recogni-
tion, such as mouse bone marrow transplant models.
Other groups have utilized luciferase expression for anal-
ysis of lymphocyte homing following adoptive transfer [1-
4]. These authors have utilized bioluminescence to per-
form elegant studies on the role of regulatory T cells in
graft versus host disease [7,8]. We feel that our T-Lux
model improves on previous luciferase models through
the generation of T-cell-specific bioluminescence. Limit-
ing luciferase expressing to the T cell compartment ena-
bles the specific study of T cell dynamics within the intact
mouse and eliminates potential confounding factors,
such as an alteration of the normal TCR clonal precursor
frequency that can affect T cell dynamics in adoptive trans-
fer studies [26].
A current limitation of the T-lux model is the attenuation
of bioluminescent signal from T cells in deeper tissues.
This is due to light absorption by superficial tissues situ-
ated between the T cell source and the detector when
imaging cells within deeper organs. Decreased or attenu-
ated luciferase signal is particularly apparent in the case of
interference within blood rich organs, such as spleen, as
hemoglobin absorbs light in the wavelength emitted by
the luciferase enzyme [42]. However, this limitation only
affects absolute quantitation of T cells within deep tissues,
while relative quantitation and dynamic changes over
time are unaffected, as demonstrated herein. Further, the
orientation of the animal can offset much of this limita-
tion, depending on the tissue of interest (e.g., spleen).
Finally, recent advances in the development of tomo-
graphic luminescent imaging instruments that can gener-
ate 3D images promise to enhance both sensitivity and
spatial resolution of the T cell signal using this model, and
should permit finer mapping of the real-time dynamics of
T cell distribution to all tissue sites in future studies.
Conclusion
We have characterized a novel transgenic mouse model
that utilizes T-cell specific luciferase bioluminescence for
tracking T cell homing and migration dynamics in vivo. To
our knowledge, this represents the first report of real-time,
in vivo analysis of CD4+ T cell homeostatic proliferation
and clonal response to antigen. Although our results are
largely confirmatory of prior studies that have examined T
cell responses through direct tissue-based analyses of T
cell numbers and distribution, implementation of the T-
lux model has provided some important new insights,
and highlights certain advantages of this approach for
tracking the in vivo T cell response.
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